{"id":"bmab1200","safety":{"commonSideEffects":[]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"As a monoclonal antibody in phase 3 development by Biocon Biologics, Bmab1200 is designed to bind to its molecular target with high specificity. The exact mechanism remains proprietary, but the antibody format suggests it functions through immune modulation, receptor blockade, or antigen neutralization. Further clinical data from phase 3 trials will clarify its precise therapeutic mechanism.","oneSentence":"Bmab1200 is a monoclonal antibody targeting a specific immune or disease-related antigen to modulate immune response or block pathogenic signaling.","_ai_confidence":"low"},"_scrapedAt":"2026-03-28T01:04:29.629Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[]},"trialDetails":[{"nctId":"NCT05335356","phase":"PHASE3","title":"Comparing Efficacy and Safety of Bmab 1200 and Stelara in Patients With Moderate to Severe Chronic Plaque Psoriasis","status":"COMPLETED","sponsor":"Biocon Biologics UK Ltd","startDate":"2022-06-28","conditions":"Moderate to Severe Chronic Plaque Psoriasis","enrollment":384},{"nctId":"NCT06738277","phase":"PHASE1","title":"This is Comparative Study in Normal Healthy Subjects to Evaluate Pharmacokinetics, Safety, Tolerability of Bmab 1200 -Autoinjector (AI) After Single Subcutaneous Injection (45 mg) in Comparison With Bmab 1200 -Prefilled Syringe (PFS).","status":"COMPLETED","sponsor":"Biocon Biologics UK Ltd","startDate":"2025-01-09","conditions":"Moderate to Severe Chronic Plaque Psoriasis","enrollment":186}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Bmab1200","genericName":"Bmab1200","companyName":"Biocon Biologics UK Ltd","companyId":"biocon-biologics-uk-ltd","modality":"Biologic","firstApprovalDate":"","aiSummary":"","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":1,"withResults":1},"verificationStatus":"partial","dataCompleteness":{"mechanism":true,"indications":false,"safety":false,"trials":true,"score":2}}